D. Young

Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity.

E. Perez, S. Chan, J. Hamm, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary.

P. Taylor, W. Andersen, W. Peters, 1989, Gynecologic oncology.

Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial

A. Kaye, A. Wickremesekera, T. Fitzjohn, 2021, Journal of Clinical Neuroscience.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

E. Perez, Y. Chia, J. Hamm, 2013, The Lancet. Oncology.

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

G. Garcia-Manero, S. Dakhil, N. Pemmaraju, 2018, Blood.